Mapping of dopamine D3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system

Journal of Receptor and Signal Transduction Research

Volumn 18, Issue 2-3, 1998, Pages 133-150

  Lundstrom, K ^a,b,c   Turpin, M P ^a   Large, C ^a   Robertson, G ^a   Thomas, P ^a   Lewell, X Q ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXO INST FOR MOLECULAR BIOLOGY   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 3 RECEPTOR; BACTERIORHODOPSIN; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DRD3 PROTEIN, HUMAN; LIGAND; RECOMBINANT PROTEIN;

ANIMAL CELL; ARTICLE; BINDING SITE; CHO CELL; DRUG RECEPTOR BINDING; GENE MUTATION; IN SITU HYBRIDIZATION; LIGAND BINDING; NONHUMAN; RECEPTOR AFFINITY; SEMLIKI FOREST ALPHAVIRUS; SITE DIRECTED MUTAGENESIS; VIRUS EXPRESSION; VIRUS MUTANT; AMINO ACID SEQUENCE; ANIMAL; BINDING COMPETITION; BIOSYNTHESIS; CELL LINE; CHEMICAL STRUCTURE; COMPARATIVE STUDY; GENETICS; HAMSTER; HUMAN; METABOLISM; MOLECULAR GENETICS; RADIOASSAY; SEQUENCE ALIGNMENT; STATISTICAL ANALYSIS;

ALPHAVIRUS; ANIMALIA; SEMLIKI FOREST VIRUS;

AMINO ACID SEQUENCE; ANIMALS; BACTERIORHODOPSINS; BINDING, COMPETITIVE; CELL LINE, TRANSFORMED; CHO CELLS; CRICETINAE; DATA INTERPRETATION, STATISTICAL; DOPAMINE AGENTS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECOMBINANT PROTEINS; SEMLIKI FOREST VIRUS; SEQUENCE ALIGNMENT;

EID: 0031595788     PISSN: 10799893     EISSN: None     Source Type: Journal    
DOI: 10.3109/10799899809047741     Document Type: Article

References (28)

1. Schenker, E. and Herbst, H., in Progress in Drug Research, edited by E. Jucker, p. 269-280, Birkhauser, Basel, 1963.
2. Carlsson, A. Some aspects of dopamine in the central nervous system. Adv. Neurol. 5, 59-68, 1974.
3. 3) as a target for neuroleptics. Nature 347, 146-151, 1990.
4. Civelli, O.; Burzon, J.R.; Grandy, D.K.; Zhou, Q.-J. and van Tol., H.H.M. Molecular biology of the dopamine receptors. Eur. J. Pharmacol., 207, 277-286, 1991.
5. 1. Nature 350, 614-619, 1991.
6. Jenno, P. and Marsden, C.D., in Drugs in Central Nervous System Disorders, edited by D.C. Horvell, p. 149-262, Marcel Dekker, New York, 1985.
7. 3 receptor mRNA and binding sites in human brain. Brain Res. Mol. Brain Res. 18, 187-192, 1993.
8. 3) as a novel target for antipsychotics. Biochem. Pharmacol. 43, 659-666, 1992.
9. Sokoloff, P.; Diaz, J.; Levesque, D.; Pilon, C.; Dimitriadou, V.; Griffon, N.; Lammers, C.H.; Martres, M.-P. and Schwarz, J.C. Novel dopamine receptor subtypes as targets for antipsychotic drugs Ann. N. Y. Acad. Sci. 757, 278-292, 1995.
10. 3 receptor: basic and clinical aspects. Clin. Neuropharmacol. 16, 295-314, 1993.
11. Liljestrom, P. and Garoff, H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Bio/Technology 9, 1356-1361, 1991.
12. Henderson, R.; Baldwin, J.M. and Ceska, T.A. Model for the structure of bacteriorhodopsin based on high resolution electron cryo-microscopy. J. Mol. Biol. 213, 899-929, 1990.
13. Maniatis, T.; Fritsch, E.F. and Sambrook, J., Molecular cloning. A laboratory manual Cold Spring Harbor, New York, 1982.
14. 3 receptor with the Semliki Forest virus system. Biochem. Biophys. Res. Comm. 225, 1068-1072, 1996.
15. Lundstrom, K.; Ahti, H. and Ulmanen, I., in Site-directed mutagenesis and protein engineering, edited by M.P. El-Gewely, p. 119-122, Elsevier Science Publisher, Amsterdam, 1991.
16. Berglund, P.; Sjoberg, M.; Garoff, H.; Atkins, G.J.; Sheahan, B.J. and Liljestrom, P. Semliki Forest virus expression system: Production of conditionally infectious recombinant particles. Bio/Technology 11, 916-920, 1993.
17. Lundstrom, K.; Mills, A.; Buell, G.; Allet, E.; Adami, N. and Liljestrom, P. High-level expression of the human neurokinin-1 receptor in mammalian cell lines using the Semliki Forest virus expression system. Eur. J. Biochem. 224, 917-921, 1994.
18. Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685, 1970.
19. Bylund, D.B. and Yamamura, H.I., in Methods in neurotransmitter receptor analysis, edited by H.I. Yamamura; S.J. Enna and M.J. Kuhar, p. 1-35, Raven Press, New York, 1990.
20. 3 receptor. Bioorg. & Med. Chem. Lett. 6, 403-408, 1995.
21. 3 receptor. Bioorg. & Med. Chem. Lett. 5, 219-222, 1995.
22. Rovati, G.E.; Rodbard, D. and Munson, P.J. DESIGN: computerized optimization of experimental design for estimating Kd and Bmax in ligand binding experiments. I. Homologous and heterologous binding to one or two classes of sites. Anal. Biochem. 174, 636-649, 1988.
23. Lewell, X.Q. A model of the adrenergic beta-2 receptor and binding sites for agonist and antagonist. Drug Des. Discov. 9, 38-48, 1992.
24. 2 receptor. Eur. J. Pharmacol. 227, 205-214, 1992.
25. Wheeler, T.N.; Blanchard, S.G.; Andrews, R.C.; Fang, F.; Gray-Nunez, Y.; Harris, C.O.; Lambert, M.H.; Mehrotra, M.M.; Parks, D.J.; Ray, J.A. and Smalley, T.L. Substrate specificity in short-chain phospholipid analogs at the active site of human synovial phospholipase A2. J. Med. Chem. 37, 4118-4129, 1994.
26. 2 Receptors. J. Neurochem. 59, 627-635, 1992.
27. Guan, X.M; Peroutka, S.J. and Kobilka, B.K. Identification of a single amino acid residue responsible for the binding of a class of β-adrenergic receptor antagonists to 5-hydroxytryptamine 1A receptors. Mol. Pharmacol. 41, 695-698, 1992.
28. 3 dopamine receptor. Biochem Soc. Trans. 27, 143S, 1994.